Heterocyclic compounds as inhibitors of beta-lactamases

Details Heterocyclic compounds as inhibitors of beta-lactamases Heterocyclic compounds as inhibitors of beta-lactamases

2004-07-26

2009-11-03

Wang, Shengjun (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S299000, C514S295000, C514S203000

Reexamination Certificate

active

07612087

ABSTRACT:
This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a β-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a β-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed.

REFERENCES:
patent: 5719141 (1998-02-01), Rasetti et al.
patent: 5932587 (1999-08-01), Schmeck et al.
patent: 5994340 (1999-11-01), Maiti et al.
patent: 7288549 (2007-10-01), Aszodi et al.
patent: 2003/0199541 (2003-10-01), Lampilas et al.
patent: 2004/0157826 (2004-08-01), Lampilas et al.
patent: 2006/0046995 (2006-03-01), Lampilas et al.
patent: 2006/0189652 (2006-08-01), Lampilas et al.
patent: 2007/0299108 (2007-12-01), Aszodi et al.
patent: 0260057 (1988-03-01), None
patent: 0702004 (1996-03-01), None
patent: 0818197 (1998-01-01), None
patent: 2676230 (1992-11-01), None
patent: 5339263 (1993-12-01), None
patent: 90/15058 (1990-12-01), None
patent: 95/09175 (1995-04-01), None
patent: WO 95/18129 (1995-07-01), None
patent: 96/29327 (1996-09-01), None
patent: 97/23484 (1997-07-01), None
patent: WO 97/25309 (1997-07-01), None
patent: WO 98/05659 (1998-02-01), None
patent: 99/01434 (1999-01-01), None
patent: 99/16442 (1999-04-01), None
patent: WO 99/21855 (1999-05-01), None
patent: 99/52875 (1999-10-01), None
patent: 00/00479 (2000-01-01), None
patent: 00/12507 (2000-03-01), None
patent: 00/37458 (2000-06-01), None
patent: 00/63187 (2000-10-01), None
patent: 01/25228 (2001-04-01), None
patent: 01/79206 (2001-10-01), None
patent: WO0210172 (2002-02-01), None
patent: 02/067937 (2002-09-01), None
patent: 02/100860 (2002-12-01), None
patent: 03/063864 (2003-08-01), None
Hall, H. K. Jr., Polymerization and ring strain in bridged bicyclic compounds, Journal of the American Chemical Society, vol. 80, 1958, pp. 6412-6420.
Hall, H. K., Jr. et al, Anti-Bredt molecules. 3. 3-Oxa-1-azabicyclo[3.3.1]nonan-2-one and 6-oxa-1-azabicyclo[3.2.1]octan-7-one, two atom-bridged bicyclic urethanes possessing bridgehead nitrogen, Journal of Organic Chemistry, vol. 45(26), 1980, pp. 5325-5328.
Bonnefoy, Alain et al., “In Vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor,” Journal of Antimicrobial Chemotherapy, vol. 54, No. 2, 2004, pp. 410-417.
Booker-Milburn, K.I. et al., “Azabenzocycloheptenones. Part 20. Synthesis and utilisation of 4-amino-1,2,3,4-tetrahydro-1(1H)-benzazepines,” J. Chem. Soc., Perkin Trans. 1: Organic and Bio-Organic Chemistry, pp. 3261-3273 (1997).
Chen, et al, Synthesis of N-substituted 1,6-Dihydro-3(2H)-Pyridinones and 1-Acyl-3-Piperidones, Heterocycles, vol. 22, No. 12, pp. 2769-2773 (1984).
Elliott, R. et al., “Syntheses and stereochemistry of 4-hydroxy tetrahydroisoquinolines in the 1-benzyl and 1-phenethyl series. Efficient routes to isopavines and homoisopavines,” Tetrahedron Letters, vol. 21, pp. 4633-4636 (1980).
Hall, Jr. et al., “3-Isopropyl-1,3-diazabicyclo[3,3,1]nonan-2-one, a Simple Bicyclic Urea with a Bridgehead Nitrogen Atom”, J. Org. Chem., vol. 37, Issue 5, pp. 697-699 (1972).
Hall, Jr. et al, “Anti-Bredt Bridgehead Nitrogen Compounds in Ring-Opening Polymerization”, Chemical Reviews, vol. 83, Issue 5, pp. 549-555 (1983).
Heier, R.F. et al., “An asymmetric synthesis of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo-[4,5,1-ij]quinolin-2(1H)-one and its [2-14C]- and [6,7-3H2]-labeled forms,” CAPLUS Database, Chemical Abstracts Service, Columbus, Ohio (1997).
Heier, R.F. et al., “Synthesis and Biological Activities of (R)-5,6-Dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and Its Metabolites,” J. Med. Chem., vol. 40, pp. 639-646 (1997).
Itoh, “Synthesis and Structure of 4-Substituted Decahydroisoquinoline Derivatives”, Chem. Pharm. Bull., vol. 16, Issue 3, pp. 455-470 (1968).
Levasseur, P. et al., “Efficacy of NXL104 (Previously AVE1330A), a Novel Broad Spectrum β-Lactamase Inhibitor, in Combination with Ceftazidime (CAZ) in Murine Septicaemia and Pneumonia”, Presentation No. F-1164, 46th ICAAC, San Francisco, CA, Dec. 17, 2005, 1 page (Abstract only).
Levasseur, P. et al., “NXL104, a Novel β-Lactamase Inhibitor, Restores the Bactericidal Activity of Ceftazidime against ESBL and AmpC Producing Strains of Enterobacteriaceae”, Presentation No. F-127, 46th ICAAC, San Francisco, CA, Dec. 17, 2005, 2 pages (Abstract and Poster Presentation).
Masumoto, S. et al., “Preparation of tricyclic quinazolinediones as poly (ADP-ribose) polymerase inhibitors,” CAPLUS Database, Chemical Abstracts Service, Columbus, Ohio (2001).
Moon, M.W. et al., “Dopaminergic and Serotonergic Activities of Imidazoquinolinones and Related Compounds,” J. Med. Chem., vol. 35, pp. 1076-1092 (1992).
Moon, M.W. et al., “Medicinal chemistry of imidazoquinolinone dopamine receptor agonists,” CAPLUS Database, Chemical Abstracts Service, Columbus, Ohio (1994).
Moon, M.W. et al., “Synthesis of tritium-labeled (R)-5-(di[2,3-3H2]propylamino)-5,6-dihydro-4H-imidazo-[4,5,1-ij]quinolin-2(1H)-one([3H]U-86170) and (R)-5-([2,3-3H2]propylamino)-5,6-dihydro-4H-imidazo-[4,5,1-ij]quinolin-2(1H)-one([3H]U-91356),” CAPLUS Database, Chemical Abstracts Service, Columbus, Ohio (1993).
Nagagsaka, T. et al., “Preparation of 1,4-dihydro-4-phenyl-3,5-pyridinedicarboxylic acids as calcium antagonists,” CAPLUS Database, Chemical Abstracts Service, Columbus, Ohio (1994).
Nicolaou, et al., “New Synthetic Technology for the Rapid Construction of Novel Heterocycles—Part 2. The Reaction of IBX with Anilides and Related Compounds”, Chem. Int. Ed., vol. 39, Issue 3, pp. 625-628 (2000).
Novexel Press Release, Novexel Announces Phase I Clinical Trial of NXL104, A Novel Broad-Spectrum Beta-Lactamase Inhibitor, Dec. 18, 2006, Paris, France, 2 pages, Downloaded Jul. 2, 2008, (www.novexel.com/IMG/pdf/CM—NXL104—Phase—1—PR—FINAL.pdf).

Affiliated with

Also associated with

Rating

Heterocyclic compounds as inhibitors of beta-lactamases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic compounds as inhibitors of beta-lactamases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds as inhibitors of beta-lactamases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4088757